# Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule

> **NCT00289744** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 178 (actual)

## Conditions studied

- Hepatitis B
- Hepatitis A

## Interventions

- **BIOLOGICAL:** TWINRIX™ ADULT
- **BIOLOGICAL:** Engerix TM

## Key facts

- **NCT ID:** NCT00289744
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-02-16
- **Primary completion:** 2009-04-15
- **Final completion:** 2009-04-15
- **Target enrollment:** 178 (ACTUAL)
- **Last updated:** 2018-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00289744

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00289744, "Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,6 Month Schedule". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00289744. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*